Launched in February 2012, We Work for Health Virginia is comprised of more than 30 organizations including the Virginia Chamber of Commerce, Virginia BIO, the Fairfax Chamber of Commerce, The National Federation of Independent Business (NFIB) Virginia, the Greater Washington Board of Trade, the Medical Society of Virginia, the MS Society, the Lupus Foundation of America, Leukemia-Lymphoma Society, Rx Partnership, the Psychiatric Society of Virginia, and the Arthritis Foundation.
Our chairs include Barry DuVal, President and CEO of the Virginia Chamber of Commerce; John Newby, CEO of VABIO: former Senator Edd Houck: and Mark Herzog, Vice President with kaléo.
Coalition members have recently held events and met with Senators Tim Kaine and Mark Warner, and Congresswoman Spanberger, and Congressmen, Cline, Riggleman,and Griffith. We have hosted events with Governor Northam, Governor McAuliffe, and Governor McDonnell, and have highlighted the economic impact of the 3,400 clinical trials that have taken place in the Commonwealth since 1999. These clinical trials have helped to fight the 6 most chronic diseases facing Virginians: cancer, stroke, diabetes, heart disease, asthma and mental illness.
The biopharmaceutical sector is the foundation of one of Virginia’s most dynamic innovation and business ecosystems. Not only does the industry invest heavily in the research and development of new treatments and cures, it also generates high quality jobs, powers economic output and exports for the U.S. economy and sustains a very large-scale supply chain.
Update
Read our statement of opposition on HR 3.
Supporting High Quality Jobs in Virginia
The innovative biopharmaceutical sector directly supported 9,706 jobs in Virginia in 2017. These jobs are often high-skill, high-wage professions.
The industry also supported another 30,911 jobs indirectly, for a total of about 40,617 jobs across the Virginia economy. These additional jobs are with vendors and suppliers such as construction companies and I.T. companies, and jobs generated by the sector’s employees such as day care centers and restaurants.
Virginia workers whose jobs were supported by the biopharmaceutical sector paid a total of $623 million in personal taxes in 2017—$551.4 million in federal taxes and $71.6 million in state taxes.
Virginia's Economic Impact
In 2017, the biopharmaceutical sector supported $9.9 billion in economic output for the state of Virginia—including $4.4 billion generated directly by the sector, and another $5.5 billion through its vendors and suppliers and through the economic activity of its workforce.
Direct Output per Direct Employee in 2017
vendor relationships
vendor spending
$589,743,635
Find Your
Elected Officials
Partners
Co-Chairs
Barry DuVal, President and CEO, Virginia Chamber of Commerce
John Newby, CEO, VirginiaBio
Former Senator Edd Houck
Mark Herzog, Vice President, kaléo
Partners
American Cancer Society
American Heart Association
American Lung Association
American Urological Association
Arthritis Foundation
AMPEL Biosolutions
Center for Rural Virginia
Dulles Regional Chamber of Commerce
Greater Richmond Urban League
Greater Washington Board of Trade
Immune Deficiency Foundation
Juvenile Diabetes Research Foundation – Virginia Chapter
kaléo Pharma
Leukemia & Lymphoma Society of Virginia
Lupus Foundation of America DC/MD/VA Chapter
Medical Society of Virginia
NAMI Virginia
National Multiple Sclerosis Society Central Virginia
National Patient Advocate Foundation
Neurofibromatosis Foundation- Mid-Atlantic
NFIB - Virginia Chapter
Northern Virginia Chamber of Commerce
Prevent Blindness Mid-Atlantic
Psychiatric Society of VA
Rx Partnership
Technology Hampton Roads
Virginia Asian Chamber of Commerce
The Virginia Hispanic Chamber of Commerce
Virginia BIO
Virginia Breast Cancer Foundation
Virginia Commonwealth University
Virginia Chamber of Commerce
Virginia Hemophilia Foundation
